Grants & Programs

Portfolio

Through our partnership with Ludwig Cancer Research, together we have established a unique and mutually beneficial approach to partnering with biotech and pharmaceutical companies that has allowed us to gain access to several of the most highly sought-after immunotherapeutic agents for inclusion in next-generation CVC clinical studies. - See more at: http://cancerresearch.org/grants-programs/clinical-accelerator/clinical-portfolio#sthash.084bQ0WY.dpuf

Through our partnership with Ludwig Cancer Research, together we have established a unique and mutually beneficial approach to partnering with biotech and pharmaceutical companies that has allowed us to gain access to several of the most highly sought-after immunotherapeutic agents for inclusion in next-generation CVC clinical studies. Below are clinical trials supported as of May 2015.

 

Direct Investment 

  • A first-in-human single ascending dose study of TRX518 in subjects with unresectable stage III or stage IV malignant melanoma or other solid tumor malignancies (NCT01239134)
    • Henry Koon, M.D., University Hospitals, Cleveland, OH
    • Dale Shepard, M.D., Ph.D., Cleveland Clinic, Cleveland, OH
    • Jedd D. Wolchok, M.D., Ph.D., and Margaret Callahan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY
  • A phase I study of NY-ESO-1 vaccine in combination with ipilimumab in patients with unresectable or metastatic melanoma, for whom treatment with ipilimumab is indicated (NCT01810016)
    • Jonathan S. Cebon, Ph.D., FRACP, Austin Health/Ludwig Cancer Research, Melbourne, Australia
    • Craig E. Devoe, M.D., North Shore LIJ, North Shore University Hospital, Manhasset, NY
    • Philip Friedlander, M.D., Icahn School of Medicine at Mount Sinai, New York, NY
    • Michael A. Postow, M.D., Memorial Sloan Kettering Cancer Center, New York, NY
    • Craig L. Slingluff Jr., M.D., University of Virginia Cancer Center, Charlottesville, VA
    • Hussein Tawbi, M.D., Ph.D., University of Pittsburgh Cancer Institute, Pittsburgh, PA
  • A phase I study to evaluate the safety and tolerability of anti-PD-L1, MEDI4736, in combination with tremelimumab in subjects with advanced solid tumors (NCT01975831)
    • Kunle Odunsi, M.D., Ph.D., Anna-Maria Kellen Clinical Investigator, Roswell Park Cancer Institute, Buffalo, NY
    • Patrick Ott, M.D., Ph.D., Dana-Farber Cancer Institute, Boston, MA
    • Jedd D. Wolchok, M.D., Ph.D., and Margaret Callahan, M.D., Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY
  • A phase II study to evaluate the clinical efficacy and safety of standards of care in combination with checkpoint blockade in patients with glioblastoma (NCT02336165)
    • David Reardon, M.D., Dana-Farber Cancer Institute, Boston, MA
  • Phase I/II study of chemo-immunotherapy with Toll-like receptor 8 agonist VTX-2337 and checkpoint blockade in subjects with recurrent, platinum-resistant ovarian cancer for whom pegylated liposomal doxorubicin (PLD) is indicated
    • George Coukos, M.D., Ph.D., University Hospital of Lausanne, Lausanne, Switzerland

 

Drugs Supply and Related Investments

  • Production of NY-ESO-1 overlapping peptides for use in a variety of trials
    • PolyPeptide Laboratories San Diego, San Diego, CA
  • Poly-ICLC manufacture and stability testing
    • Oncovir, Inc., Washington, DC
  • A multi-peptide vaccine plus Toll-like receptor agonists in melanoma patients, with evaluation of the injection site microenvironment for resected stage IIB-IV (NCT01585350)
    • Craig L. Slingluff Jr., M.D., University of Virginia Cancer Center, Charlottesville, VA
  • A phase I open label, multicenter, multi-ascending dose trial evaluating the safety, tolerability, and immunogenicity of intramuscular recombinant NY-ESO-1 protein with GLA-SE adjuvant in patients with unresectable or metastatic cancer expressing NY-ESO-1 cancer (NCT02015416)
    • Immune Design, Seattle, WA
  • A phase I study of cancer vaccine CHP-NY-ESO-1 in combination with Poly-ICLC in patients with esophageal cancer or malignant melanoma expressing NY-ESO-1 (NCT01003808)
    • Hiroshi Shiku, M.D., and Shinichi Kageyama, M.D., Mie University School of Medicine, Mie, Japan
  • A phase I study of concomitant WT1 analog peptide and NY-ESO-1
    • David O’Malley, M.D., The Ohio State University Wexner Medical Center, Columbus, OH
    • Paul Sabbatini, M.D., Memorial Sloan Kettering Cancer Center, New York, NY
  • A phase I study of vaccination with NY-ESO-1 protein mixed with Poly-ICLC, OK-432 (Picibanil®), and ISA-51 (Montanide®) in patients with advanced cancers expressing NY-ESO-1 antigen (UMIN000007954)
    • Yuichiro Doki, Ph.D., and Hisashi Wada, M.D., Ph.D., Osaka University, Osaka, Japan
  • A phase IA/IB study of vaccination with NY-ESO-1 protein, Poly-ICLC, and mogamulizumab in patients with adult T cell leukemia/lymphoma expressing NY-ESO-1 antigen
    • Yuzuru Kanakura, Ph.D., and Hiroyoshi Nishikawa, M.D., Ph.D., Osaka University, Osaka, Japan
  • A pilot study of a novel multimodality immuno-chemotherapy platform for patients with advanced cutaneous T cell lymphoma (NCT02061449)
    • Catherine M. Diefenbach, M.D., NYU Langone Medical Center, New York, NY
  • A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus Poly-ICLC in stage IB-IIIA breast cancer (NCT01532960)
    • Patrick M. Dillon, M.D., University of Virginia Cancer Center, Charlottesville, VA
  • Evaluation of safety and immunogenicity of a multiphosphapeptide vaccine plus Poly-ICLC in participants with melanoma (NCT01846143)
    • Victor H. Engelhard, Ph.D., and Craig L. Slingluff Jr., M.D., University of Virginia Cancer Center, Charlottesville, VA
  • Phase I study of NY-ESO-1 protein + Poly-ICLC +/- Montanide® ISA-51 VG vaccine in patients with advanced malignant melanoma (NCT01079741)
    • Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY
       
  • Phase I/II trial of a long peptide vaccine (LPV8) + TLR agonists for resected stage IIB-IV (Mel60) (NCT02126579)
    • Craig L. Slingluff Jr., M.D., University of Virginia Cancer Center, Charlottesville, VA
  • Safety and immunogenicity of vaccination with XAGE1b long peptides combined with Poly-ICLC in patients with stage III/IV pulmonary adenocarcinoma
    • Christian Taube, M.D., and Maarten L. Zandvliet, Ph.D., Leiden University Medical Center, Leiden, The Netherlands

 

Correlative and laboratory Investments

  • Development of cancer immunotherapy targeting regulatory T cells
    • Hiroyoshi Nishikawa, M.D., Ph.D., Osaka University, Osaka, Japan
  • Early-phase NY-ESO-1 clinical trials in patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and monitoring of tumor-specific immune responses
    • Maha Ayyoub, Ph.D., and Danila Valmori, Ph.D., Centre de Lutte Contre Le Cancer Nantes-Atlantique, Nantes, France
       
  • Immunological monitoring for the CVC trials
    • Sacha Gnjatic, Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY
  • NY-ESO-1 and mixed bacterial vaccine clinical trials and immune monitoring
    • Elke Jäger, M.D., Krankenhaus Nordwest, Frankfurt, Germany
  • Phase II study of CTLA-4 blockade and low dose cyclophosphamide in patients with advanced malignant melanoma after failure of at least one prior therapy
    • Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mount Sinai, New York, NY
    • Anna C. Pavlick, D.O., NYU Langone Medical Center, New York, NY
       
  • Preclinical toxicity studies to enable the clinical development of the XAGE1b peptide vaccine
    • Cornelis J.M. Melief, M.D., Ph.D., Leiden University Medical Center, Leiden, The Netherlands
       
  • Vaccination of melanoma patients (stage II-IV) with ImmuFact IMP321, tumor antigenic peptides, and Montanide
    • Daniel E. Speiser, M.D., University Hospital of Lausanne, Lausanne, Switzerland

 

Clinical Strategy Team Grants

  • TBD – first round of 7 this year